In the present study, unsupervised identification of therapy-resistant AML blasts in MC12 (CD3-CD7- CD33- CD38- CD64- HLA-DR- CD117- CD135-) using FlowSOM, or detection of MRD cells by manual gating, may represent important predictive markers of early relapse or long-term survival that could aid in more accurate selection of the appropriate therapy or populations needed for allo-HCT (46, 47). The gene discussed is CD7; the disease is acute myeloid leukemia.